JB Pharma, one of the fastest growing pharmaceutical companies in India, has entered into an agreement with Glenmark Pharmaceuticals Ltd., to acquire the entire Razel (rosuvastatin) franchise for the India and Nepal region for a whopping Rs. 314 crore.
With this acquisition, JB Pharma will complete its cardiac portfolio making it a leader in this segment, as Razel ranks among the top 10 brands in the rosuvastatin molecule category in the country. These brands are focused on the cardiac segment in India and Nepal Commenting on the acquisition, Nikhil Chopra, CEO & whole time director, JB Pharma said,
